235 related articles for article (PubMed ID: 30171547)
1. Systemic Injection of Peptide-PMOs into Humanized DMD Mice and Evaluation by RT-PCR and ELISA.
Melo D; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():263-273. PubMed ID: 30171547
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.
Maruyama R; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554
[TBL] [Abstract][Full Text] [Related]
3. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
Maruyama R; Yokota T
Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
6. Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene.
Echigoya Y; Lim KRQ; Melo D; Bao B; Trieu N; Mizobe Y; Maruyama R; Mamchaoui K; Tanihata J; Aoki Y; Takeda S; Mouly V; Duddy W; Yokota T
Mol Ther; 2019 Nov; 27(11):2005-2017. PubMed ID: 31416775
[TBL] [Abstract][Full Text] [Related]
7. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
8. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
9. Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy.
Maruyama R; Echigoya Y; Caluseriu O; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2017; 1565():201-213. PubMed ID: 28364245
[TBL] [Abstract][Full Text] [Related]
10. Restoring Dystrophin Expression with Exon 44 and 53 Skipping in the DMD Gene in Immortalized Myotubes.
Echigoya Y; Yokota T
Methods Mol Biol; 2023; 2587():125-139. PubMed ID: 36401027
[TBL] [Abstract][Full Text] [Related]
11. Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.
Echigoya Y; Nakamura A; Nagata T; Urasawa N; Lim KRQ; Trieu N; Panesar D; Kuraoka M; Moulton HM; Saito T; Aoki Y; Iversen P; Sazani P; Kole R; Maruyama R; Partridge T; Takeda S; Yokota T
Proc Natl Acad Sci U S A; 2017 Apr; 114(16):4213-4218. PubMed ID: 28373570
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Evaluation of Single-Exon and Multiexon Skipping in mdx52 Mice.
Mizobe Y; Miyatake S; Takizawa H; Hara Y; Yokota T; Nakamura A; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1828():275-292. PubMed ID: 30171548
[TBL] [Abstract][Full Text] [Related]
13. Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():165-171. PubMed ID: 30171541
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.
Lim KRQ; Echigoya Y; Nagata T; Kuraoka M; Kobayashi M; Aoki Y; Partridge T; Maruyama R; Takeda S; Yokota T
Mol Ther; 2019 Jan; 27(1):76-86. PubMed ID: 30448197
[TBL] [Abstract][Full Text] [Related]
16. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice.
Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y
Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046
[TBL] [Abstract][Full Text] [Related]
17. PMO Delivery System Using Bubble Liposomes and Ultrasound Exposure for Duchenne Muscular Dystrophy Treatment.
Negishi Y; Ishii Y; Nirasawa K; Sasaki E; Endo-Takahashi Y; Suzuki R; Maruyama K
Methods Mol Biol; 2018; 1687():185-192. PubMed ID: 29067664
[TBL] [Abstract][Full Text] [Related]
18. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
Popplewell LJ; Malerba A; Dickson G
Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
[TBL] [Abstract][Full Text] [Related]
19. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy.
Komaki H; Nagata T; Saito T; Masuda S; Takeshita E; Sasaki M; Tachimori H; Nakamura H; Aoki Y; Takeda S
Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669851
[TBL] [Abstract][Full Text] [Related]
20. Golodirsen for Duchenne muscular dystrophy.
Anwar S; Yokota T
Drugs Today (Barc); 2020 Aug; 56(8):491-504. PubMed ID: 33025945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
